Basic Information
| RNALocate ID: | RLID:01002345 |
| RNA Symbol: | hsa-miR-193b-3p |
| Localization: | Nucleus |
RNA Information
| RNA Name: | hsa-miR-193b |
| RNA ID: | miRBase:MIMAT0002819 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 21363885 |
| Tissue/Cell Line: | Neural progenitor cells |
| Method: | Microarray|qRT-PCR |
| Description: | The miRNAs with nuclear or cytoplasmic dominance are shown in Table 1 (complete data in Supplement 4). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002338 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01002339 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01002340 | Mitochondrion | Myotube | 27396686 |
| RLID:01002341 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002342 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01002343 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01002344 | Nucleolus | HeLa cells | 23940654 |
| RLID:11003004 | Exosome | Primary ovarian tumor cells|Serum | 18589210 |
| RLID:11003005 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11003006 | Exosome | Brain tissue | 23382797 |
| RLID:11003007 | Exosome | Plasma | 23663360 |
| RLID:11003008 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11003009 | Exosome | Plasma | 24683445 |
| RLID:11003010 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11003011 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11003012 | Microvesicle | Follicular fluid | 23666971 |
| RLID-D:11000154 | Exosome | B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Tongue tissue | |
| RLID-D:11000486 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-193b-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-23139 |
| MNDR | hsa-miR-193b-3p | Oral squamous cell carcinoma | MNDR-E-MI-23140 |
| MNDR | hsa-miR-193b-3p | Medulloblastoma | MNDR-E-MI-23141 |
| MNDR | hsa-miR-193b-3p | Lymphoma | MNDR-E-MI-23142 |
| MNDR | hsa-miR-193b-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-23143 |
| MNDR | hsa-miR-193b-3p | Dermatomyositis | MNDR-E-MI-23144 |
| MNDR | hsa-miR-193b-3p | Prostate cancer | MNDR-E-MI-23145 |
| MNDR | hsa-miR-193b-3p | Gastric cancer | MNDR-E-MI-23146 |
| MNDR | hsa-miR-193b-3p | Alzheimer disease | MNDR-E-MI-23147 |
| MNDR | hsa-miR-193b-3p | Intracranial aneurysm | MNDR-E-MI-23148 |
| MNDR | hsa-miR-193b-3p | Dysautonomia familial | MNDR-E-MI-23149 |
| MNDR | hsa-miR-193b-3p | Myotonic dystrophy | MNDR-E-MI-23150 |
| MNDR | hsa-miR-193b-3p | Muscular dystrophy duchenne | MNDR-E-MI-23151 |
| MNDR | hsa-miR-193b-3p | Head and neck cancer | MNDR-E-MI-23152 |
| MNDR | hsa-miR-193b-3p | Leukemia | MNDR-E-MI-23153 |
| MNDR | hsa-miR-193b-3p | Huntington disease | MNDR-E-MI-23154 |
| MNDR | hsa-miR-193b-3p | Chorea | MNDR-E-MI-23155 |
| MNDR | hsa-miR-193b-3p | Cardiovascular disease | MNDR-E-MI-23156 |
| MNDR | hsa-miR-193b-3p | Lung cancer | MNDR-E-MI-23157 |
| MNDR | hsa-miR-193b-3p | Fragile x syndrome | MNDR-E-MI-23158 |
| MNDR | hsa-miR-193b-3p | Parkinson disease | MNDR-E-MI-23159 |
| MNDR | hsa-miR-193b-3p | Basal-like breast cancer | MNDR-E-MI-23160 |
| MNDR | hsa-miR-193b-3p | Neuroendocrine neoplasia | MNDR-E-MI-23161 |
| MNDR | hsa-miR-193b-3p | Thyroid cancer | MNDR-E-MI-23162 |
| MNDR | hsa-miR-193b-3p | Pancreatic cancer | MNDR-E-MI-23163 |
| MNDR | hsa-miR-193b-3p | Melanoma | MNDR-E-MI-23164 |
| MNDR | hsa-miR-193b-3p | Rectum adenocarcinoma | MNDR-E-MI-23165 |
| MNDR | hsa-miR-193b-3p | Colon cancer | MNDR-E-MI-23166 |
| MNDR | hsa-miR-193b-3p | Ischemic attack transient | MNDR-E-MI-23167 |
| MNDR | hsa-miR-193b-3p | Colon adenocarcinoma | MNDR-E-MI-23168 |
| MNDR | hsa-miR-193b-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-23169 |
| MNDR | hsa-miR-193b-3p | Familial ovarian cancer | MNDR-E-MI-23170 |
| MNDR | hsa-miR-193b-3p | Glioblastoma | MNDR-E-MI-23171 |
| MNDR | hsa-miR-193b-3p | Glioma | MNDR-E-MI-23172 |
| MNDR | hsa-miR-193b-3p | Central nervous system lymphoma | MNDR-E-MI-23173 |
| MNDR | hsa-miR-193b-3p | Chordoma | MNDR-E-MI-23174 |
| MNDR | hsa-miR-193b-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-23175 |
| MNDR | hsa-miR-193b-3p | Epilepsy temporal lobe | MNDR-E-MI-23176 |
| MNDR | hsa-miR-193b-3p | Osteosarcoma | MNDR-E-MI-23177 |
| MNDR | hsa-miR-193b-3p | Inclusion body myositis | MNDR-E-MI-23178 |
| MNDR | hsa-miR-193b-3p | Infarction middle cerebral artery | MNDR-E-MI-23179 |
| MNDR | hsa-miR-193b-3p | Meningioma | MNDR-E-MI-23180 |
| MNDR | hsa-miR-193b-3p | Cervical adenocarcinoma | MNDR-E-MI-23181 |
| MNDR | hsa-miR-193b-3p | Gastric adenocarcinoma | MNDR-E-MI-23182 |
| MNDR | hsa-miR-193b-3p | Cervical squamous cell carcinoma | MNDR-E-MI-23183 |
| MNDR | hsa-miR-193b-3p | Lung squamous cell carcinoma | MNDR-E-MI-23184 |
| MNDR | hsa-miR-193b-3p | Non-small cell lung cancer | MNDR-E-MI-23185 |
| MNDR | hsa-miR-193b-3p | Lung adenocarcinoma | MNDR-E-MI-23186 |
| MNDR | hsa-miR-193b-3p | Thyroid carcinoma | MNDR-E-MI-23187 |
| MNDR | hsa-miR-193b-3p | Bladder urothelial carcinoma | MNDR-E-MI-23188 |
| MNDR | hsa-miR-193b-3p | Pancreatic adenocarcinoma | MNDR-E-MI-23189 |
| MNDR | hsa-miR-193b-3p | Brain stem cancer | MNDR-E-MI-23190 |
| MNDR | hsa-miR-193b-3p | Carcinoma renal cell | MNDR-E-MI-23191 |
| MNDR | hsa-miR-193b-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-23192 |
| MNDR | hsa-miR-193b-3p | Renal clear cell carcinoma | MNDR-E-MI-23193 |
| MNDR | hsa-miR-193b-3p | Large cell carcinoma | MNDR-E-MI-23194 |
| MNDR | hsa-miR-193b-3p | Biliary tract cancer | MNDR-E-MI-23195 |
| MNDR | hsa-miR-193b-3p | Cholangiocarcinoma | MNDR-E-MI-23196 |
| MNDR | hsa-miR-193b-3p | Esophageal cancer | MNDR-E-MI-23197 |
| MNDR | hsa-miR-193b-3p | Oncocytoma | MNDR-E-MI-23198 |
| MNDR | hsa-miR-193b-3p | Lung small cell carcinoma | MNDR-E-MI-23199 |
| MNDR | hsa-miR-193b-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-23200 |
| MNDR | hsa-miR-193b-3p | Uveal melanoma | MNDR-E-MI-23201 |
| MNDR | hsa-miR-193b-3p | Hepatocellular carcinoma | MNDR-E-MI-23202 |
| MNDR | hsa-miR-193b-3p | Familiar ovarian carcinoma | MNDR-E-MI-23203 |
| MNDR | hsa-miR-193b-3p | Chronic kidney disease | MNDR-E-MI-23204 |
| MNDR | hsa-miR-193b-3p | Hodgkin lymphoma | MNDR-E-MI-23205 |
| MNDR | hsa-miR-193b-3p | Burkitt lymphoma | MNDR-E-MI-23206 |
| MNDR | hsa-miR-193b-3p | Skin cutaneous melanoma | MNDR-E-MI-23207 |
| MNDR | hsa-miR-193b-3p | Skin melanoma | MNDR-E-MI-23208 |
| MNDR | hsa-miR-193b-3p | Autosomal dominant polycystic kidney disease | MNDR-E-MI-23209 |
| MNDR | hsa-miR-193b-3p | Acute myeloid leukemia | MNDR-E-MI-23210 |
| MNDR | hsa-miR-193b-3p | Colorectal cancer | MNDR-E-MI-23211 |
| MNDR | hsa-miR-193b-3p | Nasopharynx carcinoma | MNDR-E-MI-23212 |
| MNDR | hsa-miR-193b-3p | Multiple myeloma | MNDR-E-MI-23213 |
| MNDR | hsa-miR-193b-3p | Nasopharyngeal cancer | MNDR-E-MI-23214 |
| MNDR | hsa-miR-193b-3p | Epstein-barr virus infections | MNDR-E-MI-23215 |
| MNDR | hsa-miR-193b-3p | Brain injury chronic | MNDR-E-MI-23216 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ACTB | Homo sapiens | RR00036852 |
TOP